Targets › SSTR4
12 programs from 12 companies in 42 trials: 22 Phase 2, 12 Phase 1, 5 Phase 3, 3 Phase 4; Oncology, Gastroenterology, Metabolic and endocrine; next expected readout Nov 2026.
Receptor for somatostatin-14. The activity of this receptor is mediated by G proteins which inhibits adenylyl cyclase. (UniProt, P31391)
Open in Phaseline: the race on SSTR4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University Hospital, Antwerp | Somatostatin Somatostatin receptor agonist | SSTR5, SSTR2, SSTR4, SSTR1, SSTR3 | Phase 4 | Gastroenteropancreatic Neuroendocrine Tumor | Apr 2029 |
| HTA | Lutetium Oxodotreotide Lu-177 Somatostatin receptor binding agent | SSTR5, SSTR2, SSTR4, SSTR1, SSTR3 | Phase 3 | NETS Ga68 Lu177 | Nov 2026 |
| Advanced Accelerator Applications | Lutetium Oxodotreotide Lu-177 Somatostatin receptor binding agent | SSTR5, SSTR2, SSTR4, SSTR1, SSTR3 | Phase 3 | Gastro-enteropancreatic Neuroendocrine Tumor; Gastroenteropancreatic Neuroendocrine Tumors; Digestive System Neuroendocrine Tumor G1; Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs) … | Oct 2027 |
| Sinotau Pharmaceutical Group | Lutetium Oxodotreotide Lu-177 Somatostatin receptor binding agent | SSTR5, SSTR2, SSTR4, SSTR1, SSTR3 | Phase 3 | Neuroendocrine Tumors | Dec 2028 |
| Washington University School of Medicine | Somatostatin Somatostatin receptor agonist | SSTR5, SSTR2, SSTR4, SSTR1, SSTR3 | Phase 3 | Neuroendocrine Neoplasm | Nov 2034 |
| The Netherlands Cancer Institute | Somatostatin Somatostatin receptor agonist | SSTR5, SSTR2, SSTR4, SSTR1, SSTR3 | Phase 2 | Neuroendocrine Tumors | Jan 2027 |
| Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 177Lu-DOTATOC Somatostatin receptor-targeted radionuclide therapy with lutetium-177 | SSTR1, SSTR2, SSTR3, SSTR4, SSTR5 | Phase 2 | Neuroendocrine Tumors | Jan 2027 |
| Australasian Gastro-Intestinal Trials Group | Somatostatin Somatostatin receptor agonist | SSTR5, SSTR2, SSTR4, SSTR1, SSTR3 | Phase 2 | Neuroendocrine Tumors | Sep 2027 |
| CSPC ZhongQi Pharmaceutical Technology | Octreotide Somatostatin receptor agonist | SSTR5, SSTR2, SSTR4, SSTR1, SSTR3 | Phase 2 | Gastroenteropancreatic Neuroendocrine Tumors; Pancreas Head Cancer | Aug 2028 |
| RayzeBio | RYZ401 Ac-225-based targeted alpha therapy for somatostatin receptor expression | SSTR1, SSTR2, SSTR3, SSTR4, SSTR5 | Phase 1 | GEP-NET | Feb 2027 |
| Novartis | Lutetium Oxodotreotide Somatostatin receptor binding agent | SSTR5, SSTR2, SSTR4, SSTR1, SSTR3 | Phase 1 | Glioblastoma; Extensive Stage Small Cell Lung Cancer | May 2027 |
| Jason Winnick | Somatostatin Somatostatin receptor agonist | SSTR5, SSTR2, SSTR4, SSTR1, SSTR3 | Phase 1 | Hypoglycemia; Iatrogenic | May 2028 |
Neuroendocrine Tumors (10) Metastatic Pancreatic Neuroendocrine Tumor (3) Gastroenteropancreatic Neuroendocrine Tumor (2) Gastroenteropancreatic Neuroendocrine Tumors (2) Meningioma (2) Glioblastoma (1) Extensive Stage Small Cell Lung Cancer (1) Neuroendocrine Neoplasm (1) Hypoglycemia; Iatrogenic (1) NETS Ga68 Lu177 (1) Gastro-enteropancreatic Neuroendocrine Tumor (1) Digestive System Neuroendocrine Tumor G1 (1)
small molecule (5), mixed (4), protein or peptide (3)
Novartis (1) University Hospital, Antwerp (1) Washington University School of Medicine (1) Sinotau Pharmaceutical Group (1) Jason Winnick (1) HTA (1) Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS (1) Australasian Gastro-Intestinal Trials Group (1) Advanced Accelerator Applications (1) CSPC ZhongQi Pharmaceutical Technology (1) The Netherlands Cancer Institute (1) RayzeBio (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.